全文获取类型
收费全文 | 54406篇 |
免费 | 5028篇 |
国内免费 | 79篇 |
专业分类
耳鼻咽喉 | 330篇 |
儿科学 | 1521篇 |
妇产科学 | 1227篇 |
基础医学 | 7524篇 |
口腔科学 | 1021篇 |
临床医学 | 6634篇 |
内科学 | 9672篇 |
皮肤病学 | 736篇 |
神经病学 | 4807篇 |
特种医学 | 2104篇 |
外国民族医学 | 3篇 |
外科学 | 7201篇 |
综合类 | 982篇 |
一般理论 | 71篇 |
预防医学 | 6835篇 |
眼科学 | 1300篇 |
药学 | 4158篇 |
中国医学 | 80篇 |
肿瘤学 | 3307篇 |
出版年
2023年 | 283篇 |
2022年 | 392篇 |
2021年 | 1091篇 |
2020年 | 627篇 |
2019年 | 1000篇 |
2018年 | 1105篇 |
2017年 | 848篇 |
2016年 | 932篇 |
2015年 | 1111篇 |
2014年 | 1488篇 |
2013年 | 2084篇 |
2012年 | 3249篇 |
2011年 | 3242篇 |
2010年 | 1865篇 |
2009年 | 1709篇 |
2008年 | 2891篇 |
2007年 | 3112篇 |
2006年 | 2963篇 |
2005年 | 2893篇 |
2004年 | 2823篇 |
2003年 | 2657篇 |
2002年 | 2413篇 |
2001年 | 1325篇 |
2000年 | 1306篇 |
1999年 | 1185篇 |
1998年 | 634篇 |
1997年 | 523篇 |
1996年 | 482篇 |
1995年 | 396篇 |
1994年 | 436篇 |
1993年 | 406篇 |
1992年 | 861篇 |
1991年 | 822篇 |
1990年 | 795篇 |
1989年 | 699篇 |
1988年 | 712篇 |
1987年 | 677篇 |
1986年 | 619篇 |
1985年 | 681篇 |
1984年 | 558篇 |
1983年 | 445篇 |
1982年 | 286篇 |
1981年 | 303篇 |
1980年 | 273篇 |
1979年 | 466篇 |
1978年 | 352篇 |
1976年 | 284篇 |
1974年 | 286篇 |
1973年 | 264篇 |
1972年 | 270篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Christopher Teng JiaDe Yu Jesse Taylor Adam I. Rubin James R. Treat 《Pediatric dermatology》2019,36(5):697-701
Erosive pustular dermatosis of the scalp (EPDS) is an uncommon chronic inflammatory response to scalp trauma that usually resolves with cicatricial alopecia. It most commonly affects elderly patients with a history of actinic damage. Herein, we describe a 16‐year‐old girl with acrofacial dysostosis type 1 presenting after surgery with crusting purulent scalp lesions, whose clinical presentation and histopathologic findings were consistent with EPDS. A review of the literature on EPDS in children is also detailed. 相似文献
3.
4.
5.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
6.
7.
Sweeka Alexander Gurjeet Dulku Sharbell Hashoul Donna B Taylor 《Journal of Medical Imaging and Radiation Oncology》2019,63(4):473-478
Contrast‐enhanced spectral mammography (CESM) has a number of uses including the work‐up of inconclusive findings on mammography, assessment of breast symptoms, cancer staging, evaluation of response to neoadjuvant chemotherapy and recently as an alternative to magnetic resonance imaging (MRI) in high‐risk screening. CESM can be swiftly incorporated into the workflow of busy breast clinics. We share our experiences with CESM at a large breast assessment centre in Western Australia. 相似文献
8.
9.
Turnbull Chris D. Stockley James A. Madathil Shyam Huq Syed S. A. Cooper Brendan G. Ali Asad Wharton Simon Stradling John R. Heitmar Rebekka 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(7):2129-2139
Graefe's Archive for Clinical and Experimental Ophthalmology - Retinal microvascular endothelial dysfunction is thought to be of importance in the development of ocular vascular diseases.... 相似文献
10.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献